CN114246925A - 一种中药精油及其应用 - Google Patents
一种中药精油及其应用 Download PDFInfo
- Publication number
- CN114246925A CN114246925A CN202011002501.5A CN202011002501A CN114246925A CN 114246925 A CN114246925 A CN 114246925A CN 202011002501 A CN202011002501 A CN 202011002501A CN 114246925 A CN114246925 A CN 114246925A
- Authority
- CN
- China
- Prior art keywords
- essential oil
- coronavirus
- chinese medicine
- extract
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000341 volatile oil Substances 0.000 title claims abstract description 129
- 239000003814 drug Substances 0.000 title claims abstract description 64
- 239000000284 extract Substances 0.000 claims abstract description 59
- 241000711573 Coronaviridae Species 0.000 claims abstract description 45
- 241000894006 Bacteria Species 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 29
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 26
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims abstract description 18
- 244000223014 Syzygium aromaticum Species 0.000 claims abstract description 18
- 241000735527 Eupatorium Species 0.000 claims abstract description 16
- 235000017803 cinnamon Nutrition 0.000 claims abstract description 14
- 240000009138 Curcuma zedoaria Species 0.000 claims abstract description 13
- 235000003405 Curcuma zedoaria Nutrition 0.000 claims abstract description 13
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 claims abstract description 13
- 235000019509 white turmeric Nutrition 0.000 claims abstract description 13
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 12
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 12
- 208000001528 Coronaviridae Infections Diseases 0.000 claims abstract description 11
- 244000166675 Cymbopogon nardus Species 0.000 claims abstract description 10
- 235000018791 Cymbopogon nardus Nutrition 0.000 claims abstract description 10
- 208000035143 Bacterial infection Diseases 0.000 claims abstract description 9
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 9
- 208000022362 bacterial infectious disease Diseases 0.000 claims abstract description 9
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 9
- 241000218378 Magnolia Species 0.000 claims abstract description 8
- 235000004347 Perilla Nutrition 0.000 claims abstract description 8
- 244000124853 Perilla frutescens Species 0.000 claims abstract description 8
- 235000014375 Curcuma Nutrition 0.000 claims abstract description 6
- 244000164480 Curcuma aromatica Species 0.000 claims abstract description 6
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 6
- 235000011477 liquorice Nutrition 0.000 claims abstract description 6
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract 2
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims abstract 2
- 240000001949 Taraxacum officinale Species 0.000 claims abstract 2
- 239000000463 material Substances 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 229940096437 Protein S Drugs 0.000 claims description 15
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 15
- 101710198474 Spike protein Proteins 0.000 claims description 15
- 241000588747 Klebsiella pneumoniae Species 0.000 claims description 14
- 244000063299 Bacillus subtilis Species 0.000 claims description 13
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 13
- 241000588724 Escherichia coli Species 0.000 claims description 13
- 241000315672 SARS coronavirus Species 0.000 claims description 13
- 241000191967 Staphylococcus aureus Species 0.000 claims description 13
- 238000000605 extraction Methods 0.000 claims description 12
- 229910052751 metal Inorganic materials 0.000 claims description 12
- 239000002184 metal Substances 0.000 claims description 12
- 241000202726 Bupleurum Species 0.000 claims description 11
- 241000607618 Vibrio harveyi Species 0.000 claims description 10
- 239000002199 base oil Substances 0.000 claims description 9
- 241000607471 Edwardsiella tarda Species 0.000 claims description 8
- 235000020230 cinnamon extract Nutrition 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 238000001256 steam distillation Methods 0.000 claims description 8
- 241000607528 Aeromonas hydrophila Species 0.000 claims description 7
- 241000607594 Vibrio alginolyticus Species 0.000 claims description 7
- 235000008216 herbs Nutrition 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000008169 grapeseed oil Substances 0.000 claims description 6
- 239000012676 herbal extract Substances 0.000 claims description 6
- 238000000222 aromatherapy Methods 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims description 4
- 239000000645 desinfectant Substances 0.000 claims description 4
- 241000607598 Vibrio Species 0.000 claims description 3
- 241000607534 Aeromonas Species 0.000 claims description 2
- 244000144725 Amygdalus communis Species 0.000 claims description 2
- 235000011437 Amygdalus communis Nutrition 0.000 claims description 2
- 241000220317 Rosa Species 0.000 claims description 2
- 239000008168 almond oil Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 229940069445 licorice extract Drugs 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
- 241000288673 Chiroptera Species 0.000 claims 2
- 241000008910 Severe acute respiratory syndrome-related coronavirus Species 0.000 claims 2
- 238000002360 preparation method Methods 0.000 abstract description 11
- 235000013399 edible fruits Nutrition 0.000 abstract description 4
- 241000212948 Cnidium Species 0.000 abstract description 2
- 241000555682 Forsythia x intermedia Species 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 35
- 230000000840 anti-viral effect Effects 0.000 description 22
- 230000000844 anti-bacterial effect Effects 0.000 description 19
- 241000628997 Flos Species 0.000 description 18
- 241000700605 Viruses Species 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 230000006870 function Effects 0.000 description 15
- 241000723347 Cinnamomum Species 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 230000000903 blocking effect Effects 0.000 description 12
- 239000003921 oil Substances 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 9
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 9
- 241001570521 Lonicera periclymenum Species 0.000 description 9
- 230000002354 daily effect Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 241000245665 Taraxacum Species 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229920000742 Cotton Polymers 0.000 description 5
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 5
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 5
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 5
- -1 aromatherapy Substances 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 5
- 229940010454 licorice Drugs 0.000 description 5
- 239000004745 nonwoven fabric Substances 0.000 description 5
- 230000002633 protecting effect Effects 0.000 description 5
- 230000035943 smell Effects 0.000 description 5
- 238000001179 sorption measurement Methods 0.000 description 5
- SCCDQYPEOIRVGX-UHFFFAOYSA-N Acetyleugenol Chemical compound COC1=CC(CC=C)=CC=C1OC(C)=O SCCDQYPEOIRVGX-UHFFFAOYSA-N 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000001331 nose Anatomy 0.000 description 4
- 235000019476 oil-water mixture Nutrition 0.000 description 4
- LVHLZMUFIYAEQB-UHFFFAOYSA-N perilla ketone Chemical compound CC(C)CCC(=O)C=1C=COC=1 LVHLZMUFIYAEQB-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 229950005143 sitosterol Drugs 0.000 description 4
- 230000002936 tranquilizing effect Effects 0.000 description 4
- 240000004784 Cymbopogon citratus Species 0.000 description 3
- 235000017897 Cymbopogon citratus Nutrition 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- KFFCKOBAHMGTMW-LGQRSHAYSA-N Forsythin Chemical compound C1=C(OC)C(OC)=CC=C1[C@H]1[C@@H](CO[C@@H]2C=3C=C(OC)C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=CC=3)[C@@H]2CO1 KFFCKOBAHMGTMW-LGQRSHAYSA-N 0.000 description 3
- 240000000691 Houttuynia cordata Species 0.000 description 3
- 235000013719 Houttuynia cordata Nutrition 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- JJVGFDTWFVSBIM-UHFFFAOYSA-N Phillyrin Natural products COc1ccc(cc1OC)C2OCC3C2COC3c4ccc(OC)c(OC5OC(CO)C(O)C(O)C5O)c4 JJVGFDTWFVSBIM-UHFFFAOYSA-N 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- KYWSCMDFVARMPN-LCSVLAELSA-N Saikosaponin D Chemical compound O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(C[C@@H](O)[C@]67CO[C@]5([C@@H]6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)CO)O[C@@H]([C@@H]1O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KYWSCMDFVARMPN-LCSVLAELSA-N 0.000 description 3
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 3
- 230000000843 anti-fungal effect Effects 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 230000000767 anti-ulcer Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 3
- 229960004949 glycyrrhizic acid Drugs 0.000 description 3
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 3
- 235000019410 glycyrrhizin Nutrition 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 229930192014 saikosaponin Natural products 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- XWMMEBCFHUKHEX-MRTCRTFGSA-N (+)-Taraxasterol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC[C@]1(C)[C@@H]2CC[C@H]2[C@@H]3[C@H](C)C(=C)CC[C@]3(C)CC[C@]21C XWMMEBCFHUKHEX-MRTCRTFGSA-N 0.000 description 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 2
- QMKPCZNFLUQTJZ-UHFFFAOYSA-N (4aR)-10c-Hydroxy-1t.2c.4ar.6at.6bc.9.9.12ac-octamethyl-(8atH.12btH.14acH.14btH)-docosahydro-picen Natural products CC1CCC2(C)CCC3(C)C(CCC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C QMKPCZNFLUQTJZ-UHFFFAOYSA-N 0.000 description 2
- RXBQNMWIQKOSCS-UHFFFAOYSA-N (7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl)methanol Chemical compound C1C2C(C)(C)C1CC=C2CO RXBQNMWIQKOSCS-UHFFFAOYSA-N 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- BAHMQESJBKGPTE-UHFFFAOYSA-N 1,5,8-trimethyl-3a,4-dihydroazuleno[6,5-b]furan-2,6-dione Chemical compound C1C2OC(=O)C(C)=C2C=C2C(C)=CC(=O)C2=C1C BAHMQESJBKGPTE-UHFFFAOYSA-N 0.000 description 2
- OQIOHYHRGZNZCW-UHFFFAOYSA-N 2-methyl-5-propan-2-ylbenzene-1,4-diol Chemical compound CC(C)C1=CC(O)=C(C)C=C1O OQIOHYHRGZNZCW-UHFFFAOYSA-N 0.000 description 2
- MJPMPMZXJIZPRE-UHFFFAOYSA-N 3-butyl-5,6,7,7a-tetrahydro-3h-2-benzofuran-1-one Chemical compound C1CCC=C2C(CCCC)OC(=O)C21 MJPMPMZXJIZPRE-UHFFFAOYSA-N 0.000 description 2
- BGEBZHIAGXMEMV-UHFFFAOYSA-N 5-methoxypsoralen Chemical compound O1C(=O)C=CC2=C1C=C1OC=CC1=C2OC BGEBZHIAGXMEMV-UHFFFAOYSA-N 0.000 description 2
- 241000112286 Bat SARS-like coronavirus Species 0.000 description 2
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 2
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 2
- 244000037364 Cinnamomum aromaticum Species 0.000 description 2
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 2
- 235000021511 Cinnamomum cassia Nutrition 0.000 description 2
- 241001354243 Corona Species 0.000 description 2
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 2
- KRCZYMFUWVJCLI-UHFFFAOYSA-N Dihydrocarveol Chemical compound CC1CCC(C(C)=C)CC1O KRCZYMFUWVJCLI-UHFFFAOYSA-N 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000005770 Eugenol Substances 0.000 description 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
- 239000004378 Glycyrrhizin Substances 0.000 description 2
- PGCKDCPTJAQQSQ-UHFFFAOYSA-N Isolicoflavonol Chemical compound C1=C(O)C(CC=C(C)C)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 PGCKDCPTJAQQSQ-UHFFFAOYSA-N 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 206010035737 Pneumonia viral Diseases 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- 240000000513 Santalum album Species 0.000 description 2
- 235000008632 Santalum album Nutrition 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 102100021696 Syncytin-1 Human genes 0.000 description 2
- LSQXNMXDFRRDSJ-UHFFFAOYSA-N Thymol methyl ether Chemical compound COC1=CC(C)=CC=C1C(C)C LSQXNMXDFRRDSJ-UHFFFAOYSA-N 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- KGEKLUUHTZCSIP-HOSYDEDBSA-N [(1s,4s,6r)-1,7,7-trimethyl-6-bicyclo[2.2.1]heptanyl] acetate Chemical compound C1C[C@]2(C)[C@H](OC(=O)C)C[C@H]1C2(C)C KGEKLUUHTZCSIP-HOSYDEDBSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229940076810 beta sitosterol Drugs 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 2
- 229940116229 borneol Drugs 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- CRPUJAZIXJMDBK-UHFFFAOYSA-N camphene Chemical compound C1CC2C(=C)C(C)(C)C1C2 CRPUJAZIXJMDBK-UHFFFAOYSA-N 0.000 description 2
- NVEQFIOZRFFVFW-RGCMKSIDSA-N caryophyllene oxide Chemical compound C=C1CC[C@H]2O[C@]2(C)CC[C@H]2C(C)(C)C[C@@H]21 NVEQFIOZRFFVFW-RGCMKSIDSA-N 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- NEHNMFOYXAPHSD-UHFFFAOYSA-N citronellal Chemical compound O=CCC(C)CCC=C(C)C NEHNMFOYXAPHSD-UHFFFAOYSA-N 0.000 description 2
- 235000001671 coumarin Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000001877 deodorizing effect Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 229960002217 eugenol Drugs 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- HKQYGTCOTHHOMP-UHFFFAOYSA-N formononetin Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O HKQYGTCOTHHOMP-UHFFFAOYSA-N 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- IGWDEVSBEKYORK-UHFFFAOYSA-N isoimperatorin Chemical compound O1C(=O)C=CC2=C1C=C1OC=CC1=C2OCC=C(C)C IGWDEVSBEKYORK-UHFFFAOYSA-N 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 235000008777 kaempferol Nutrition 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004630 mental health Effects 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- HFPZCAJZSCWRBC-UHFFFAOYSA-N p-cymene Chemical compound CC(C)C1=CC=C(C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- RUMOYJJNUMEFDD-UHFFFAOYSA-N perillyl aldehyde Chemical compound CC(=C)C1CCC(C=O)=CC1 RUMOYJJNUMEFDD-UHFFFAOYSA-N 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- NGFFRJBGMSPDMS-UHFFFAOYSA-N psi-Taraxasterol Natural products CC12CCC(O)C(C)(C)C1CCC1(C)C2CCC2C3C(C)C(C)=CCC3(C)CCC21C NGFFRJBGMSPDMS-UHFFFAOYSA-N 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- HUTYZQWCTWWXND-NCTFTGAASA-N taraxasterol Natural products C[C@H]1[C@H]2C3=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)C[C@H](O)[C@@]2(C)CCC1=C HUTYZQWCTWWXND-NCTFTGAASA-N 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 235000007586 terpenes Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 208000009421 viral pneumonia Diseases 0.000 description 2
- NPNUFJAVOOONJE-ZIAGYGMSSA-N β-(E)-Caryophyllene Chemical compound C1CC(C)=CCCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-ZIAGYGMSSA-N 0.000 description 2
- KDPFMRXIVDLQKX-ISGXEFFDSA-N (+)-Curdione Natural products CC(C)[C@@H]1CC(=O)[C@@H](C)CC\C=C(C)/CC1=O KDPFMRXIVDLQKX-ISGXEFFDSA-N 0.000 description 1
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- HGXBRUKMWQGOIE-AFHBHXEDSA-N (+)-pinoresinol Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@@H]3[C@@H]([C@H](OC3)C=3C=C(OC)C(O)=CC=3)CO2)=C1 HGXBRUKMWQGOIE-AFHBHXEDSA-N 0.000 description 1
- WTARULDDTDQWMU-RKDXNWHRSA-N (+)-β-pinene Chemical compound C1[C@H]2C(C)(C)[C@@H]1CCC2=C WTARULDDTDQWMU-RKDXNWHRSA-N 0.000 description 1
- WTARULDDTDQWMU-IUCAKERBSA-N (-)-Nopinene Natural products C1[C@@H]2C(C)(C)[C@H]1CCC2=C WTARULDDTDQWMU-IUCAKERBSA-N 0.000 description 1
- MATGKVZWFZHCLI-LSDHHAIUSA-N (-)-matairesinol Chemical compound C1=C(O)C(OC)=CC(C[C@@H]2[C@H](C(=O)OC2)CC=2C=C(OC)C(O)=CC=2)=C1 MATGKVZWFZHCLI-LSDHHAIUSA-N 0.000 description 1
- YLKVIMNNMLKUGJ-FPLPWBNLSA-N (15:1)-Cardanol Chemical compound CCCCCC\C=C/CCCCCCCC1=CC=CC(O)=C1 YLKVIMNNMLKUGJ-FPLPWBNLSA-N 0.000 description 1
- CWVRJTMFETXNAD-BMNNCGMMSA-N (1s,3r,4s,5r)-3-[(e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,4,5-trihydroxycyclohexane-1-carboxylic acid Chemical compound O[C@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-BMNNCGMMSA-N 0.000 description 1
- DGZBGCMPRYFWFF-ZYOSVBKOSA-N (1s,5s)-6-methyl-4-methylidene-6-(4-methylpent-3-enyl)bicyclo[3.1.1]heptane Chemical compound C1[C@@H]2C(CCC=C(C)C)(C)[C@H]1CCC2=C DGZBGCMPRYFWFF-ZYOSVBKOSA-N 0.000 description 1
- MPDGHEJMBKOTSU-WFJWTYAKSA-N (2s,4as,6as,6br,10s,12as)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-2-carboxylic acid Chemical compound C12C(=O)C=C3C4C[C@@](C)(C(O)=O)CC[C@]4(C)CC[C@@]3(C)[C@]1(C)CCC1[C@]2(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-WFJWTYAKSA-N 0.000 description 1
- NTWLPZMPTFQYQI-UHFFFAOYSA-N (3alpha)-olean-12-ene-3,23-diol Natural products C1CC(O)C(C)(CO)C2CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4=CCC3C21C NTWLPZMPTFQYQI-UHFFFAOYSA-N 0.000 description 1
- SFEUTIOWNUGQMZ-UHFFFAOYSA-N (4,4,6a,6b,8a,12,14b-heptamethyl-11-methylidene-1,2,3,4a,5,6,6a,7,8,9,10,12,12a,13,14,14a-hexadecahydropicen-3-yl) acetate Chemical compound CC12CCC(OC(C)=O)C(C)(C)C1CCC1(C)C2CCC2C3C(C)C(=C)CCC3(C)CCC21C SFEUTIOWNUGQMZ-UHFFFAOYSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- XMKLTEGSALONPH-UHFFFAOYSA-N 1,2,4,5-tetrazinane-3,6-dione Chemical compound O=C1NNC(=O)NN1 XMKLTEGSALONPH-UHFFFAOYSA-N 0.000 description 1
- BUCJHJXFXUZJHL-UHFFFAOYSA-N 1-ethylcyclohexan-1-ol Chemical compound CCC1(O)CCCCC1 BUCJHJXFXUZJHL-UHFFFAOYSA-N 0.000 description 1
- OVSQVDMCBVZWGM-LQSBFMDOSA-N 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2r,3s,4r,5r,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-LQSBFMDOSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- HCXVJBMSMIARIN-ZETWWWAOSA-N 24alpha-Ethyl-koprostanol Natural products CC[C@H](C=C[C@H](C)[C@H]1CC[C@@H]2[C@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C)C(C)C HCXVJBMSMIARIN-ZETWWWAOSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- YLKVIMNNMLKUGJ-UHFFFAOYSA-N 3-Delta8-pentadecenylphenol Natural products CCCCCCC=CCCCCCCCC1=CC=CC(O)=C1 YLKVIMNNMLKUGJ-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- KSDSYIXRWHRPMN-UHFFFAOYSA-N 4'-O-beta-D-Galactopyranoside-6''-p-Coumaroylprunin-4',5,7-Trihydroxyflavanone Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC(O)=C3C(=O)C2)C=C1 KSDSYIXRWHRPMN-UHFFFAOYSA-N 0.000 description 1
- ZPSAEGUNYMEKBP-UHFFFAOYSA-N 5-Isopentenyloxy-psoralen Natural products CC(C)C=COc1c2C=CC(=O)Oc2cc3occc13 ZPSAEGUNYMEKBP-UHFFFAOYSA-N 0.000 description 1
- NVEQFIOZRFFVFW-UHFFFAOYSA-N 9-epi-beta-caryophyllene oxide Natural products C=C1CCC2OC2(C)CCC2C(C)(C)CC21 NVEQFIOZRFFVFW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- BEYIWVKWKJROGZ-UHFFFAOYSA-N Alloimperatorin Natural products O1C(=O)C=CC2=C1C(O)=C1OC=CC1=C2OCC=C(C)C BEYIWVKWKJROGZ-UHFFFAOYSA-N 0.000 description 1
- 241000563984 Ampelopsis Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 1
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 241000132012 Atractylodes Species 0.000 description 1
- DBMJZOMNXBSRED-UHFFFAOYSA-N Bergamottin Natural products O1C(=O)C=CC2=C1C=C1OC=CC1=C2OCC=C(C)CCC=C(C)C DBMJZOMNXBSRED-UHFFFAOYSA-N 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 241000202722 Bupleurum falcatum Species 0.000 description 1
- 241001678559 COVID-19 virus Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- VMYXUZSZMNBRCN-AWEZNQCLSA-N Curcumene Natural products CC(C)=CCC[C@H](C)C1=CC=C(C)C=C1 VMYXUZSZMNBRCN-AWEZNQCLSA-N 0.000 description 1
- QRMPRVXWPCLVNI-UHFFFAOYSA-N Curcumenol Natural products C1C(=C)C2CCC(C)C22CC(C(C)C)C1(O)O2 QRMPRVXWPCLVNI-UHFFFAOYSA-N 0.000 description 1
- HUZJLWLCLJEXEL-NFAWXSAZSA-N Curcumenone Chemical compound C1C(=C(C)C)C(=O)C[C@@]2(C)[C@H](CCC(=O)C)[C@H]21 HUZJLWLCLJEXEL-NFAWXSAZSA-N 0.000 description 1
- HUZJLWLCLJEXEL-UHFFFAOYSA-N Curcumenone Natural products C1C(=C(C)C)C(=O)CC2(C)C(CCC(=O)C)C21 HUZJLWLCLJEXEL-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 241001083514 Gayophytum Species 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- KDPFMRXIVDLQKX-NHFJXKHHSA-N Germacr-1(10)-ene-5,8-dione Chemical compound CC(C)[C@@H]1CC(=O)[C@@H](C)CC\C=C(C)\CC1=O KDPFMRXIVDLQKX-NHFJXKHHSA-N 0.000 description 1
- NGGYSPUAKQMTNP-UHFFFAOYSA-N Glabrene Chemical compound C1=C(O)C=C2OCC(C3=C4OC(C=CC4=C(O)C=C3)(C)C)=CC2=C1 NGGYSPUAKQMTNP-UHFFFAOYSA-N 0.000 description 1
- KKLOCFOZPFGVBB-UHFFFAOYSA-N Glabrene Natural products C1=C(O)C=C2OCC(C3=CC=C4OC(C=CC4=C3O)(C)C)=CC2=C1 KKLOCFOZPFGVBB-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N Glycyrrhetinic acid Natural products C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- GCGBHJLBFAPRDB-UHFFFAOYSA-N Hederagenin Natural products CC1(C)CCC2(CCC3(C)C4CCC5C(C)(CO)C(O)CCC5(C)C4CC=C3C2C1)C(=O)O GCGBHJLBFAPRDB-UHFFFAOYSA-N 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 241000497005 Ixophorus unisetus Species 0.000 description 1
- PUPKKEQDLNREIM-UHFFFAOYSA-N Kaempferitin Natural products OC1C(O)C(O)C(C)OC1OC1=CC(O)=C2C(=O)C(OC3C(C(O)C(O)C(C)O3)O)=C(C=3C=CC(O)=CC=3)OC2=C1 PUPKKEQDLNREIM-UHFFFAOYSA-N 0.000 description 1
- 241000218195 Lauraceae Species 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- DEMKZLAVQYISIA-ONJCETCRSA-N Liquiritin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc([C@@H]2Oc3c(C(=O)C2)ccc(O)c3)cc1 DEMKZLAVQYISIA-ONJCETCRSA-N 0.000 description 1
- DEMKZLAVQYISIA-UHFFFAOYSA-N Liquirtin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-UHFFFAOYSA-N 0.000 description 1
- 244000167230 Lonicera japonica Species 0.000 description 1
- 235000017617 Lonicera japonica Nutrition 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 241000218394 Magnolia liliiflora Species 0.000 description 1
- KGGUASRIGLRPAX-UHFFFAOYSA-N Meranzin hydrate Natural products C1=CC(=O)OC2=C(CC(O)C(C)(C)O)C(OC)=CC=C21 KGGUASRIGLRPAX-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 244000270834 Myristica fragrans Species 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- RXBQNMWIQKOSCS-RKDXNWHRSA-N Myrtenol Natural products C1[C@H]2C(C)(C)[C@@H]1CC=C2CO RXBQNMWIQKOSCS-RKDXNWHRSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 235000009388 Parthenocissus quinquefolia Nutrition 0.000 description 1
- 244000062780 Petroselinum sativum Species 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 241001607869 Plantagineae Species 0.000 description 1
- 240000002505 Pogostemon cablin Species 0.000 description 1
- 235000011751 Pogostemon cablin Nutrition 0.000 description 1
- PXRCIOIWVGAZEP-UHFFFAOYSA-N Primaeres Camphenhydrat Natural products C1CC2C(O)(C)C(C)(C)C1C2 PXRCIOIWVGAZEP-UHFFFAOYSA-N 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- WTARULDDTDQWMU-UHFFFAOYSA-N Pseudopinene Natural products C1C2C(C)(C)C1CCC2=C WTARULDDTDQWMU-UHFFFAOYSA-N 0.000 description 1
- 208000019155 Radiation injury Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- JMFSHKGXVSAJFY-UHFFFAOYSA-N Saponaretin Natural products OCC(O)C1OC(Oc2c(O)cc(O)c3C(=O)C=C(Oc23)c4ccc(O)cc4)C(O)C1O JMFSHKGXVSAJFY-UHFFFAOYSA-N 0.000 description 1
- GCGBHJLBFAPRDB-KCVAUKQGSA-N Scutellaric acid Natural products CC1(C)CC[C@@]2(CC[C@@]3(C)[C@@H]4CC[C@H]5[C@@](C)(CO)[C@H](O)CC[C@]5(C)[C@H]4CC=C3[C@@H]2C1)C(=O)O GCGBHJLBFAPRDB-KCVAUKQGSA-N 0.000 description 1
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 241000531819 Streptomyces venezuelae Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- FZPYMZUVXJUAQA-ZDUSSCGKSA-N Turmerone Chemical compound CC(C)=CC(=O)C[C@H](C)C1=CCC(C)=CC1 FZPYMZUVXJUAQA-ZDUSSCGKSA-N 0.000 description 1
- FZPYMZUVXJUAQA-UHFFFAOYSA-N Turmerone Natural products CC(C)=CC(=O)CC(C)C1=CCC(C)=CC1 FZPYMZUVXJUAQA-UHFFFAOYSA-N 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- MOZJVOCOKZLBQB-UHFFFAOYSA-N Vitexin Natural products OCC1OC(Oc2c(O)c(O)cc3C(=O)C=C(Oc23)c4ccc(O)cc4)C(O)C(O)C1O MOZJVOCOKZLBQB-UHFFFAOYSA-N 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- SOSLMHZOJATCCP-PADPQNGGSA-N afzelin Natural products O([C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O1)C1=C(c2ccc(O)cc2)Oc2c(c(O)cc(O)c2)C1=O SOSLMHZOJATCCP-PADPQNGGSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 244000000022 airborne pathogen Species 0.000 description 1
- 230000002353 algacidal effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- JZVFJDZBLUFKCA-FXIAWGAOSA-N alpha-Spinasterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)CC[C@H]33)C)C3=CC[C@H]21 JZVFJDZBLUFKCA-FXIAWGAOSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- VYBREYKSZAROCT-UHFFFAOYSA-N alpha-myrcene Natural products CC(=C)CCCC(=C)C=C VYBREYKSZAROCT-UHFFFAOYSA-N 0.000 description 1
- JZVFJDZBLUFKCA-UTQQLQBSSA-N alpha-spinasterol Natural products CC[C@H](C=C[C@H](C)[C@H]1CC[C@H]2C3=CC[C@@H]4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C JZVFJDZBLUFKCA-UTQQLQBSSA-N 0.000 description 1
- XOCANRBEOZQNAQ-KBPBESRZSA-N alpha-turmerone Natural products O=C(/C=C(\C)/C)C[C@H](C)[C@H]1C=CC(C)=CC1 XOCANRBEOZQNAQ-KBPBESRZSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 230000002790 anti-mutagenic effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- BPYGTFFYYOWDBC-LOVSFRALSA-N arctiin Natural products COc1ccc(C[C@H]2COC(=O)[C@@H]2Cc3ccc(O[C@@H]4O[C@H](C)[C@@H](O)[C@H](O)[C@H]4O)c(OC)c3)cc1OC BPYGTFFYYOWDBC-LOVSFRALSA-N 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 1
- 229960003321 baicalin Drugs 0.000 description 1
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229930000766 bergamotene Natural products 0.000 description 1
- 229960002045 bergapten Drugs 0.000 description 1
- KGZDKFWCIPZMRK-UHFFFAOYSA-N bergapten Natural products COC1C2=C(Cc3ccoc13)C=CC(=O)O2 KGZDKFWCIPZMRK-UHFFFAOYSA-N 0.000 description 1
- NPNUFJAVOOONJE-UHFFFAOYSA-N beta-cariophyllene Natural products C1CC(C)=CCCC(=C)C2CC(C)(C)C21 NPNUFJAVOOONJE-UHFFFAOYSA-N 0.000 description 1
- 229930006722 beta-pinene Natural products 0.000 description 1
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940115397 bornyl acetate Drugs 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 229930006739 camphene Natural products 0.000 description 1
- ZYPYEBYNXWUCEA-UHFFFAOYSA-N camphenilone Natural products C1CC2C(=O)C(C)(C)C1C2 ZYPYEBYNXWUCEA-UHFFFAOYSA-N 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229940025250 camphora Drugs 0.000 description 1
- 239000010238 camphora Substances 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- NPNUFJAVOOONJE-UONOGXRCSA-N caryophyllene Natural products C1CC(C)=CCCC(=C)[C@@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-UONOGXRCSA-N 0.000 description 1
- RSYBQKUNBFFNDO-UHFFFAOYSA-N caryophyllene oxide Natural products CC1(C)CC2C(=C)CCC3OC3(C)CCC12C RSYBQKUNBFFNDO-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 239000010630 cinnamon oil Substances 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 229930003633 citronellal Natural products 0.000 description 1
- 235000000983 citronellal Nutrition 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- ISFMXVMWEWLJGJ-NZBPQXDJSA-N curcumenol Chemical compound CC1=C[C@](O2)(O)C(=C(C)C)C[C@@]22[C@@H](C)CC[C@H]21 ISFMXVMWEWLJGJ-NZBPQXDJSA-N 0.000 description 1
- 239000008540 curcumenone Substances 0.000 description 1
- KDPFMRXIVDLQKX-UHFFFAOYSA-N curdione Natural products CC(C)C1CC(=O)C(C)CCC=C(C)CC1=O KDPFMRXIVDLQKX-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 1
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- 229930007024 dihydrocarveol Natural products 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- RIKPNWPEMPODJD-UHFFFAOYSA-N formononetin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC=C2C1=O RIKPNWPEMPODJD-UHFFFAOYSA-N 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- LCWMKIHBLJLORW-UHFFFAOYSA-N gamma-carene Natural products C1CC(=C)CC2C(C)(C)C21 LCWMKIHBLJLORW-UHFFFAOYSA-N 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- PGOYMURMZNDHNS-MYPRUECHSA-N hederagenin Chemical compound C1C[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C PGOYMURMZNDHNS-MYPRUECHSA-N 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000001309 inhibitory effect on influenza Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- KRZBCHWVBQOTNZ-DLDRDHNVSA-N isochlorogenic acid Natural products O[C@@H]1[C@H](C[C@@](O)(C[C@H]1OC(=O)C=Cc2ccc(O)c(O)c2)C(=O)O)OC(=O)C=Cc3ccc(O)c(O)c3 KRZBCHWVBQOTNZ-DLDRDHNVSA-N 0.000 description 1
- ZMGSKTZDVIZXJS-UHFFFAOYSA-N kaempferitrin Natural products CC1OC(OC2C(Oc3cc(OC4OC(C)C(O)C(O)C4O)cc(O)c3C2=O)c5ccc(O)cc5)C(O)C(O)C1O ZMGSKTZDVIZXJS-UHFFFAOYSA-N 0.000 description 1
- PUPKKEQDLNREIM-QNSQPKOQSA-N kaempferol 3,7-di-O-alpha-L-rhamnoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=CC(O)=C2C(=O)C(O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)=C(C=3C=CC(O)=CC=3)OC2=C1 PUPKKEQDLNREIM-QNSQPKOQSA-N 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- DEMKZLAVQYISIA-ZRWXNEIDSA-N liquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C([C@H]2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-ZRWXNEIDSA-N 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- 235000000055 matairesinol Nutrition 0.000 description 1
- RNXYRAQIZQGUIK-UHFFFAOYSA-N matairesinol Natural products COc1cc(CC2OCC(=O)C2Cc3ccc(O)c(OC)c3)ccc1O RNXYRAQIZQGUIK-UHFFFAOYSA-N 0.000 description 1
- 239000004750 melt-blown nonwoven Substances 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- BFBPISPWJZMWJN-UHFFFAOYSA-N methyl 2-[(7-hydroxy-3,7-dimethyloctylidene)amino]benzoate Chemical compound COC(=O)C1=CC=CC=C1N=CCC(C)CCCC(C)(C)O BFBPISPWJZMWJN-UHFFFAOYSA-N 0.000 description 1
- JPTOCTSNXXKSSN-UHFFFAOYSA-N methylheptenone Chemical compound CCCC=CC(=O)CC JPTOCTSNXXKSSN-UHFFFAOYSA-N 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 239000001702 nutmeg Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 235000011197 perejil Nutrition 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 235000007221 pinoresinol Nutrition 0.000 description 1
- OHOPKHNWLCMLSW-UHFFFAOYSA-N pinoresinol Natural products C1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C(CO)C(O)=CC=3)CO2)=C1 OHOPKHNWLCMLSW-UHFFFAOYSA-N 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- GSZUGBAEBARHAW-UHFFFAOYSA-N sophoraflavone B Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=2OC3=CC(O)=CC=C3C(=O)C=2)C=C1 GSZUGBAEBARHAW-UHFFFAOYSA-N 0.000 description 1
- 230000001150 spermicidal effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- ROCZYNYGPDAYRQ-QGYXGAFPSA-N stigmasterol d-glucoside Natural products CC[C@H](C=C[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5C)C(C)C ROCZYNYGPDAYRQ-QGYXGAFPSA-N 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- BKUSDHRTBIFINS-UHFFFAOYSA-N taraxasteryl acetate Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C4CCC5(C)CCC(C)(C)CC5C4(C)CCC23)C1(C)C BKUSDHRTBIFINS-UHFFFAOYSA-N 0.000 description 1
- YMBFCQPIMVLNIU-UHFFFAOYSA-N trans-alpha-bergamotene Natural products C1C2C(CCC=C(C)C)(C)C1CC=C2C YMBFCQPIMVLNIU-UHFFFAOYSA-N 0.000 description 1
- 230000032895 transmembrane transport Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- SGEWCQFRYRRZDC-VPRICQMDSA-N vitexin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(O)C2=C1OC(C=1C=CC(O)=CC=1)=CC2=O SGEWCQFRYRRZDC-VPRICQMDSA-N 0.000 description 1
- PZKISQRTNNHUGF-UHFFFAOYSA-N vitexine Natural products OC1C(O)C(O)C(CO)OC1OC1=C(O)C=C(O)C2=C1OC(C=1C=CC(O)=CC=1)=CC2=O PZKISQRTNNHUGF-UHFFFAOYSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- BURBOJZOZGMMQF-UHFFFAOYSA-N xanthoxylol Natural products C1=C(O)C(OC)=CC=C1C1C(COC2C=3C=C4OCOC4=CC=3)C2CO1 BURBOJZOZGMMQF-UHFFFAOYSA-N 0.000 description 1
- VMYXUZSZMNBRCN-UHFFFAOYSA-N α-curcumene Chemical compound CC(C)=CCCC(C)C1=CC=C(C)C=C1 VMYXUZSZMNBRCN-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-PMTKVOBESA-N β-glycyrrhetinic acid Chemical compound C([C@@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-PMTKVOBESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A41—WEARING APPAREL
- A41D—OUTERWEAR; PROTECTIVE GARMENTS; ACCESSORIES
- A41D13/00—Professional, industrial or sporting protective garments, e.g. surgeons' gowns or garments protecting against blows or punches
- A41D13/05—Professional, industrial or sporting protective garments, e.g. surgeons' gowns or garments protecting against blows or punches protecting only a particular body part
- A41D13/11—Protective face masks, e.g. for surgical use, or for use in foul atmospheres
- A41D13/1192—Protective face masks, e.g. for surgical use, or for use in foul atmospheres with antimicrobial agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/234—Cnidium (snowparsley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Birds (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Textile Engineering (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供了一种中药精油,其中,所述中药精油包含以下中药的提取物中的一种或多种:丁香、肉桂、莪术、紫苏叶、辛夷、香茅、蛇床子、佩兰、甘草、金银花、连翘、蒲公英、柴胡,以及所述中药精油在制备用于预防冠状病毒感染和/或细菌感染的制剂中的用途。本发明提供了一种抑制冠状病毒和/或细菌的方法,所述方法包括将所述中药精油与冠状病毒和/或细菌相接触。此外,本发明还提供了一种包含所述中药精油的日用品。
Description
技术领域
本发明涉及医药技术领域,更具体地涉及一种中药精油及其在制备用于预防冠状病毒感染和/或细菌感染的制剂中的用途、一种抑制冠状病毒和/或细菌的方法、和包含该中药精油的日用品。
背景技术
冠状病毒是一个大型病毒家族,已知可引起感冒以及中东呼吸综合征(MERS)和严重急性呼吸综合征(SARS)等较严重疾病。新型冠状病毒是以前从未在人体中发现的冠状病毒新毒株。2019年12月以来,湖北省武汉市持续开展流感及相关疾病监测,发现多起病毒性肺炎病例,均诊断为病毒性肺炎/肺部感染。国际病毒分类委员会声明,将将此种新病原体命名为严重急性呼吸综合征冠状病毒2号(severe acute respiratory syndromecoronavirus 2)或SARS-CoV-2,在本发明中简称为“新冠病毒”。
新冠病毒(SARS-CoV-2)自爆发以来,引起了全球性的大流行。截止2020年7月中旬,全世界已有近1500万人感染,60余万人失去生命,造成了难以估量的损失。人感染了新冠病毒(SARS-CoV-2)后常见体征有呼吸道症状、发热、咳嗽、气促和呼吸困难等。在较严重病例中,感染可导致肺炎、严重急性呼吸综合征、肾衰竭,甚至死亡。目前对于新冠病毒(SARS-CoV-2)所致疾病没有特异治疗方法,也没有特异性针对新冠病毒(SARS-CoV-2)的抗病毒药物,疫苗研发也尚无突破性进展。
因此,抑制新冠病毒(SARS-CoV-2)的候选药物的发现迫在眉睫。
发明内容
有鉴于此,本发明提供了一种中药精油及其在制备用于预防冠状病毒感染和/或细菌感染的制剂中的用途、以及一种抑制冠状病毒和/或细菌的方法、和包含该中药精油的日用品。
根据本发明的第一方面,本发明提供了一种中药精油,其中,所述中药精油包含以下中药的提取物中的一种或多种:丁香、肉桂、莪术、紫苏叶、辛夷、香茅、蛇床子、佩兰、甘草、金银花、连翘、蒲公英、柴胡。
根据本发明的第二方面,本发明提供了一种抑制冠状病毒和/或细菌的方法,所述方法包括将本发明的第一方面所述的中药精油与冠状病毒和/或细菌相接触。
根据本发明的第三方面,本发明提供了本发明的第一方面所述的中药精油在制备用于预防冠状病毒感染和/或细菌感染的制剂中的用途。
根据本发明的第四方面,本发明提供了一种日用品,包含本发明的第一方面所述的中药精油。
本发明的有益效果:
本发明通过将对数种中药材的提取物用来制备具有抗菌、抗病毒等作用的中药精油,从而用于抑制冠状病毒和/或细菌、以及预防和/或治疗冠状病毒感染和/或细菌感染。本发明提供的中药精油不仅包含中药提取物,例如通过超临界CO2提取法或水蒸气蒸馏法提取的中药提取物,而且还包含通常用于精油制备的基油,这样制备出的中药精油不仅气味芳香,而且还具有抗菌和抗病毒的功效。
本发明还将中药精油应用到诸如口罩、消毒液、香薰、喷雾、洗手液或护肤品等日用品中,不仅可以起到抗菌和抗病毒的功效,而且味道芳香,可以使人们心情愉悦,在帮助民众预防病毒入侵,增强上呼吸道防御能力的同时,还可以使民众保持身心健康。
附图说明
为了更清楚地说明本发明实施例或现有技术中的技术方案,下面将对实施例中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图仅仅是本发明的一些实施例,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的实施方案。
图1是根据本发明的一些实施方案的低浓度精油(0.1%,以体积百分比计)的抗新冠病毒(SARS-CoV-2)作用的结果示意图;
图2是根据本发明的一些实施方案的高浓度精油(1%,以体积百分比计)的抗新冠病毒(SARS-CoV-2)作用的结果示意图;
图3是根据本发明的一些实施方案的不同浓度精油(0.003%、0.01%、0.1%、0.3%、1%,以体积百分比计)的抗病毒作用的结果示意图;
图4是实施例3的丁香、莪术、肉桂、月桂叶和香茅五种中药精油的抗菌活性的结果示意图,其中,SA:金黄色葡萄球菌;EC:大肠杆菌;KP:肺炎克雷伯氏菌;PA:铜绿假单胞菌;BS:枯草芽孢杆菌;Ah:嗜水气单胞菌;Et:迟缓爱德华氏菌;Va:解藻弧菌;Vh:哈维氏弧菌。
图5是根据本发明的一些实施方案的口罩的打开结构示意图,其中,1表示金属线,2表示药线,3表示外层,4表示中层,5表示内层。
具体实施方式
下面将结合本发明的实施方案和附图,对本发明进行清楚、完整的描述。显然,所描述的实施方案仅仅是本发明的一部分实施方案,而不是全部的实施方案。基于本发明中的实施方案,本领域普通技术人员可以获得的所有其他实施方案,都属于本发明保护的范围。
新冠病毒(SARS-CoV-2)已经引起了全球流行的传染病,然而目前对于新冠病毒所致疾病没有特异治疗方法,也没有特异性针对新冠病毒的抗病毒药物。因此,发现能够抑制冠状病毒或进一步地新冠病毒(SARS-CoV-2)的候选药物迫在眉睫。
中药是指在中医理论指导下,用于预防、治疗疾病并具有康复与保健作用的物质,历来是防病、治病和抗疫的重要物质。自古就有端午节插艾叶和戴香包的习惯,取其芳香开窍、辟秽和避疫的作用。中药由于各种药物本身各自具有若干特性和作用而能够针对病情起作用,并且许多中药都具有抗菌、抗病毒等的作用。
精油是从植物的叶子、花朵、种子、果实、根部、树皮、树脂、木心等部位以水蒸汽蒸馏法、冷压榨法、脂吸法和溶剂萃取法提炼出来的、具有高浓度芳香和挥发性的物质。纯天然的植物精油气味芬芳,自然的芳香精油进入脑部后,可刺激大脑前叶分泌出内啡肽及脑啡肽两种荷尔蒙,使精神呈现舒适的状态,并且精油还具有杀菌、抗炎、愈合、除臭、镇静、驱虫、柔润细腻皮肤等作用。虽然各种精油的化学组成差异显著,但是由于合成路径类似,很多化学成分在多种植物精油里都能找到,而精油之所以具有杀菌抗炎等功效,也是因为含有这些具有生物活性的化学成分。
基于此,本发明通过将对数种中药材的提取物用来制备具有抗菌、抗病毒等作用的中药精油,从而用于抑制冠状病毒和/或细菌、以及预防和/或治疗冠状病毒感染和/或细菌感染。
因此,根据本发明的第一方面,提供了一种中药精油,所述中药精油包含以下中药的提取物中的一种或多种:丁香、肉桂、莪术、紫苏叶、辛夷、香茅、蛇床子、佩兰、甘草、金银花、连翘、蒲公英、柴胡。
丁香,又名丁子香、支解香、公丁香。丁子香的花蕾为常用中药。现代研究表明,丁子香含挥发油15%~20%,油中主成分为丁香油酚、β-丁香烯、乙酰基丁香油酚等,另含丁香酚、乙酰丁香酚、异槲皮素、山柰酚、槲皮素、石竹烯氧化物、齐墩果酸、α-衣兰油烯等成分。丁香具有健胃作用,浸出液具有明显的刺激胃液分泌作用,并能缓解腹胀、恶心、呕吐等。另外,对多种致病性真菌、球菌、链球菌及肺炎、痢疾、大肠、伤寒等杆菌以及流感病毒有抑制作用。
肉桂,又名牡桂、紫桂、大桂,为樟科植物肉桂Cinnamomum cassia Presl的干燥树皮。肉桂对肠胃有缓和的刺激作用,并能解除胃肠平滑肌痉挛,具有很强的抗溃疡作用;可拮抗血小板聚集,具有改善心血管***的作用,调节机体免疫功能;对中枢神经***,具有镇静、镇痛、解热、抗惊厥等作用;对阳虚、阴虚模型有预防和保护作用;具有一定的抗炎作用;具有很强的杀真菌作用。
莪术,又名文莪、蓬术、羌七、广术、黑心姜、文术,主要含挥发油、黄酮类、萜类等化学成分。莪术主要有莪术呋喃烯酮、莪术醇、龙脑、大栊牛儿酮、樟脑、姜黄烯、姜黄酮、莪术二酮、桂莪术内酯、胡萝卜苷、β-谷固醇、棕榈酸等成分。莪术具有抗肿瘤、抗菌、升高白细胞、活血化瘀的作用;对胃肠平滑肌低浓度紧张、高浓度舒张;具有保肝作用;对急性肾功能衰竭有改善作用;抑制血小板聚集及抗血栓形成;具有抗炎等作用。
紫苏叶,又名苏叶、紫菜、苏,其含紫苏醛、紫苏酮,白苏酮、薄荷醇、高山黄芩苷、新西兰牡荆苷Ⅱ、鹭樱苷等成分。紫苏叶具有镇静及较弱的解热作用;可使兴奋性膜产生抑制作用;能促进消化液分泌,增强胃肠蠕动;对呼吸***,可产生止咳祛痰平喘作用,对血液***,具有止血和抗凝血双重作用;升高血糖;调节机体免疫功能,具有抗诱变能力;抗微生物,具有广谱的抗菌作用,尚有抗炎作用。
辛夷,又名木兰、紫玉兰,其含挥发油,油中主要成分为1,8-桉油精等,另含β-蒎烯、1,8-桉叶素、樟脑、望春花素、香橙烯、望春玉兰脂素A等成分,具有麻醉、抗过敏、抗炎、降压、子宫兴奋、抗血小板凝聚、抗微生物、镇痛、改善微循环作用。
香茅,又名柠檬茅、香巴茅、风茅,茎叶含挥发油0.4~0.8%,其中主要成分柠檬醛,含量达75~85%,又含少量香茅醛、牻牛儿醇和甲基庚烯酮。香茅的挥发油有抗真菌(如委内瑞拉链丝菌等)作用。治疗风湿效果颇佳,治疗偏头痛,抗感染,改善消化功能,除臭、驱虫。抗感染,收敛肌肤,调理油腻不洁皮肤。赋予清新感,恢复身心平衡(尤其生病初愈的阶段)。是芳香疗法及医疗方法中用途最广的精油。也可用于室内当芳香剂。
蛇床子,又名野茴香、野胡萝卜子、蛇米、蛇珠、蛇粟、蛇床仁。含挥发油,其主要成分为蒎稀、异缬草酸龙脑酯、欧芹酚甲醚、二氢欧山芹醇、佛手柑内酯、蛇床子素、异茴芹素等。另含台莰烯、异欧前胡素、哥伦比亚内酯、乙酸龙脑酯、柠檬烯,3-谷固醇等成分。蛇床子可以抗心律失常;抑制心脏;降血压;性激素样作用;抗真菌,杀虫、滴虫及杀精;祛痰和平喘;局部麻醉;抗***反应,抗诱变作用;延缓衰老;影响血浆***胞素和内环核苷酸的代谢;抑制平滑肌收缩;防治骨质疏松;有镇静催眠等作用。
佩兰,又名兰草、泽兰、圆梗泽兰、香水兰,其含挥发油;叶含香豆精、香豆酸、麝香草氢醌;根含兰草素。另含乙酸橙醇酯、百里香酚甲醚、对聚伞花素、蒲公英固醇乙酸酯、3-谷固醇等成分。佩兰具有祛痰、抗病毒、抗癌的作用;对流行性感冒病毒有抑制作用;并能抑制***。
甘草,又名蜜甘、甜甘草、国老、美草,其主要含甘草苷、甘草酸、甘草甜素、子丁香烯氧化物、甘草萜醇、18а-羟基甘草次酸、异甘草次酸、甘草香豆精、刺芒柄花素、新甘草查耳酮D、光果甘草苷元、异甘草黄酮醇、三萜皂苷、香豆素等成分。甘草有肾上腺皮质激素作用,抗炎、抗溃疡、抗过敏反应,抗癌,抗菌,抗病毒,促进胰液分泌,对离体肠有抑制,调节免疫功能,镇咳祛痰,抗突变,解毒,抗氧化,保护耳前庭功能、利尿,保肝、防止动脉硬化,抗脑缺血,预防糖尿病并发症等作用。
金银花,又名忍冬花、双花、二花、银花、鹭鸶花、金花、双苞花、金藤花,其含木樨草素、肌醇1%及挥发油、萜类、酚酸等化学成分。其中有绿原酸、异绿原酸、白果醇、β-谷固醇、豆固醇、豆固醇-D-葡萄糖苷等成分。金银花具有抗病原微生物、抗毒、抗炎、解热、促进炎细胞吞噬功能、降血脂、中枢兴奋、抗生育、预防胃溃疡、兴奋子宫作用。金银花的水煎剂、水浸液和提纯液,用平板打洞法,对致龋齿的变形链球菌,具有较好的杀灭和抑制作用,抑菌效果随浓度增大而明显增强。
连翘,又名落翘、黄花条、黄链条花,其含木脂素类、黄酮类、挥发性成分、苯乙烷类、乙基环己醇类、三萜类及香豆素类等化合物。还有桦木酸、连翘苷、牛蒡子苷、罗汉松脂苷、松脂素、连翘醇苷C、连翘醇苷D等。连翘具有抗微生物;抑制磷酸二酯酶、脂氧酶作用;镇吐;抗肝损伤;抗炎;抑制弹性蛋白酶活性;降低自发性高血压等。
蒲公英,又名蒲公草、地丁、蒲公丁、金簪草、狗乳草、黄花地丁,其含蒲公英甾醇、胆碱、菊糖、果胶、蒲公英固醇、蒲公英素、蒲公英赛醇、咖啡酸等成分。具有抗病原微生物作用,抗肿瘤,抗胃溃疡,利胆及保肝,低浓度时直接兴奋离体蛙心,而高浓度时则呈抑制作用。能提高离体十二指肠的紧张性并加强其收缩力,临床认为有健胃和轻泻作用。注射液在试管内对金黄色葡萄球菌耐药菌株、溶血性链球菌有较强的杀菌作用,对肺炎双球菌、脑膜炎球菌、白喉杆菌、绿脓杆菌、变形杆菌、痢疾杆菌、伤寒杆菌及卡他球菌亦有一定的杀菌作用。
柴胡,又名红柴胡、南柴胡、地熏、茈胡、山菜、茹草、柴草,其主要含戊酸、亚麻酸、棕榈酸、硬脂酸、山柰酚、山柰苷、槲皮素、芸香苷、香橙烯、龙脑、大叶柴胡皂苷Ⅱ、桃金娘醇、α-菠菜固醇、去葡萄糖基柴胡皂苷α、柴胡皂苷等成分。另含春福寿醇等成分。药理试验证明,柴胡具有抗炎、解热、镇静、镇痛、镇咳及抗惊厥作用;可减轻肝损伤和促进胆汁分泌;具有降血压、降低血清胆固醇以及溶血作用;具有抗溃疡、抗菌、抗病毒、抗肿瘤、升高血糖、降低血中脂肪含量、抗辐射损伤等作用。
在一个进一步的实施方案中,所述中药的提取物通过超临界CO2提取法或水蒸气蒸馏法提取获得。
因此,在本发明中,“提取物”是指例如通过采用超临界CO2提取法或水蒸气蒸馏法来对诸如丁香、肉桂、莪术、紫苏叶、辛夷等的中药进行提取,从而获得的包含低极性且易挥发的小分子成分的提取物。当然也可以使用本领域已知的通常用于中药提取的其他方法,本发明对此不作进一步的限定。
超临界CO2提取法是指在超临界状态下,将超临界流体与待分离的物质接触,使其有选择性地把极性大小、沸点高低和分子量大小的成分依次萃取出来。具体到本发明,将中药粉碎后加入萃取器中,向萃取器中加入少量极性溶剂(携带剂)后实现室温低压(20-30℃,100-200bar)条件,使CO2超临界流体达到亚临界流体状态,流体从下至上注入萃取器进入萃取阶段,萃取完全后,萃取液减压后先后进入第一分离器和第二分离器,在第二分离器底部收集中药提取物。
水蒸气蒸馏法是指将含有挥发性成分的植物材料与水共蒸馏,使挥发性成分随水蒸气一并馏出,经冷凝分取挥发性成分的浸提方法。具体到本发明,将粉碎后的中药放入蒸馏器内,上方接上冷却器,下方通上蒸气,使蒸气压力保持0.12Mpa-0.13Mpa。蒸气透过药粉,因蒸气的高温作用使药粉中挥发性成分气化,随水蒸气从蒸馏管进入冷却器,蒸气和气化的挥发性成分在冷却器中冷却成油水混合物,用油水分离器在冷却器出口处收集油水混合物,静置后,油水自动分离,上层为中药提取物,下层为水。使用分离器放去下层的水,即得所需的中药提取物。
中药精油可以包含一种中药的提取物,也可以包含多种(诸如两种、三种、四种、五种、六种、七种、八种、九种、十种、十一种、十二种)中药的提取物的组合。可以理解,这些中药提取物可以以任意比例组合,可以基于不同人的味道喜好来进行相应地调整。
在一个实施方案中,所述中药精油包含以下中药提取物的组合:莪术提取物+肉桂提取物、柴胡提取物+肉桂提取物、甘草提取物+丁香提取物、或佩兰提取物+柴胡提取物。进一步地,莪术提取物+肉桂提取物、柴胡提取物+肉桂提取物、甘草提取物+丁香提取物或佩兰提取物+柴胡提取物分别以(1~5):(5~1)的比例组合,例如以1:5、1:3、1:2、2:3、1:1、2:1、3:1、4:1、5:1的比例混合,优选地,以1:1的比例混合。
如本领域普通技术人员众所周知的,纯精油的刺激性十分强烈,直接擦在皮肤上,会造成伤害,并且伤害性很大,所以精油在皮肤上使用前,一定要先稀释。基油是指从植物的种子、花朵、根茎或果实中萃取的非挥发性油脂,可润滑肌肤,能直接用于肌肤按摩,其通常用来稀释单方精油(纯精油)。基油可以减少对皮肤和呼吸粘膜的刺激性,减缓精油挥发,延长使用时间。
因此,在一个实施方案中,所述中药精油还包含作为基油的甜杏仁油、玫瑰籽油或葡萄籽油中的一种、两种或三种。优选地,所述中药精油包含葡萄籽油。葡萄籽油色清、味淡,可以适合不同的皮肤。当然,也可以使用本领域已知的其他基油。
在一个实施方案中,以体积百分比计,所述中药精油中的每种所述提取物的浓度为0.003%~10%,例如,0.005%、0.008%、0.01%、0.02%、0.03%、0.04%、0.05%、0.06%、0.07%、0.08%、0.09%、0.1%、0.2%、0.3%、0.4%、0.5%、0.6%、0.7%、0.8%、0.9%、1%、2%、3%、4%、5%、6%、7%、8%、9%、或10%,或其中任何两个数值构成的数值范围之间的任意数值。
在一个实施方案中,以体积百分比计,所述中药精油中的每种所述提取物的浓度为0.1%~10%,例如0.1%~1%。
根据本发明的第二方面,本发明提供了一种抑制冠状病毒和/或细菌的方法,所述方法包括将本发明的第一方面所述的中药精油与冠状病毒和/或细菌相接触。
在本发明中,所述方法可以为用于非治疗目的的方法,用于抑制例如环境空气中、物体表面上等的冠状病毒和/或细菌;所述方法也可以为用于治疗目的的方法,例如用于人或动物受试者。
“冠状病毒”是指病毒的包膜上有形状类似日冕的棘突的一类病毒。冠状病毒粒子呈不规则形状,直径约60-220nm。病毒粒子外包着脂肪膜,膜表面有三种糖蛋白:刺突蛋白(S,Spike Protein,是受体结合位点、溶细胞作用和主要抗原位点);包膜蛋白(E,EnvelopeProtein,较小,与包膜结合的蛋白);膜蛋白(M,Membrane Protein,负责营养物质的跨膜运输、新生病毒出芽释放与病毒外包膜的形成)。
本发明的中药精油通过减少冠状病毒的刺突蛋白,可以减少刺突蛋白与血管紧张素转化酶2(ACE2)的结合,从而可以起到抑制冠状病毒的作用。因此,在一个实施方案中,所述中药精油通过减少冠状病毒外壳的刺突蛋白来抑制冠状病毒。
在一些实施方案中,所述冠状病毒为严重急性呼吸综合征冠状病毒2号(SARS-CoV-2)、严重急性呼吸综合征冠状病毒(SARS-CoV)、中东呼吸综合征冠状病毒(MERS-CoV)、或蝙蝠SARS样冠状病毒(bat-SL-CoVZC45)。
在一些实施方案中,所述细菌为金黄色葡萄球菌(Staphylococcus aureus)、大肠杆菌(Escherichia coli)、铜绿假单胞菌(Pseudomonas aeruginosa)、肺炎克雷伯氏菌(Klebsiella peneumoniae)、枯草芽孢杆菌(Bacillus subtilis,BS)、嗜水气单胞菌(Aeromonas hydrophila)、迟缓爱德华氏菌(Edwardsiella tarda)、解藻弧菌(Vibrioalginolyticus)、哈维氏弧菌(Vibrio harveyi)中的一种或者多种。
根据本发明的第三方面,本发明还提供了本发明的第一方面所述的中药精油在制备用于预防冠状病毒感染和/或细菌感染的制剂中的用途。
在一些实施方案中,所述冠状病毒为严重急性呼吸综合征冠状病毒2号(SARS-CoV-2)、严重急性呼吸综合征冠状病毒(SARS-CoV)、中东呼吸综合征冠状病毒(MERS-CoV)、或蝙蝠SARS样冠状病毒(bat-SL-CoVZC45)。
在一些实施方案中,所述细菌为金黄色葡萄球菌、大肠杆菌、铜绿假单胞菌、肺炎克雷伯氏菌、枯草芽孢杆菌、嗜水气单胞菌、迟缓爱德华氏菌、解藻弧菌、哈维氏弧菌中的一种或者多种。
根据本发明的第四方面,本发明提供了一种日用品,包含本发明的第一方面所述的中药精油。
在一些实施方案中,所述日用品为口罩、消毒液、香薰、喷雾、洗手液或护肤品。
在一些实施方案中,所述日用品为口罩,并且所述中药精油以药线的形式存在于所述口罩中。
在一些实施方案中,所述中药精油中每种所述提取物的浓度为5%-10%,例如5%、6%、7%、8%、9%或10%,或其中任何两个数值构成的范围中的任意数值。
在一些实施方案中,所述口罩为一次性口罩,包括左带、作为防水层的外层、作为过滤层的中层、作为吸水层的内层、用于夹住鼻梁的金属条和右带,并且所述药线位于所述外层和所述中层之间,例如位于所述金属条下方,例如下方0.5-2厘米。
在一个实施方案中,所述药线位于所述外层和所述中层之间,且位于所述金属条下方。
在一个实施方案中,所述药线位于所述金属条下方0.5-2厘米处,诸如下方0.5、0.6、0.7、0.8、0.9、1.0、1.1、1.2、1.3、1.4、1.5、1.6、1.7、1.8、1.9、2.0厘米或其间的任何距离处。
如本领域技术人员通常理解的,左带和右带主要用于佩戴的作用。外层主要用于防水的作用,材料为不织布,其具有拨水功能,可以防止飞沫以及大颗粒粉尘。中层主要用于过滤作用,材料为熔喷不织布,透过熔喷结网技术,能够过滤细菌和微粒。内层主要用于吸水,材料为不织布,表面亲水处理,使肌肤接触部分舒适。口罩中的金属条用于夹住鼻梁,其材质可以为例如铝、环保型全塑条等。药线为浸有中药精油的具有吸附作用的任何材料例如棉线、无纺线、棉条或无纺布条。此外,可以根据口罩调整药线的长度,例如17cm。在制造口罩时,用浸泡的方法将具有吸附作用的材料加入到中药精油中以制成药线,再放进生产机器,从而将药线放置于口罩中。当然,本领域已知的常用于口罩的上述相应结构的任何材料均可用于本发明,在此不对其进行进一步的限制。
在发明中,口罩可是本领域已知的任何口罩,可以是医用口罩或非医用口罩,可以为例如N95型口罩、医用外科口罩等。因此,可以根据不同的口罩类型,依照本发明来将药线放置在合适的位置处。
在本发明中,通过将具有吸附作用的材料泡在中药精油里吸收精油,再将含有精油的药线加到外层防水层和中层过滤层之间,优选地,在金属条下方的位置,这样一方面能避开直接接触防水层和过滤层,不会影响口罩阻隔细菌病毒的功效,另一方面,将含有中药精油的药线加在口罩内部而不是口罩表面也可以避免药线掉落而失去功效。此外,所加的药线可以适用于全自动口罩生产线。
本发明的有益效果:
本发明通过将对数种中药材的提取物用来制备具有抗菌、抗病毒等作用的中药精油,从而用于抑制冠状病毒和/或细菌、以及预防和/或治疗冠状病毒感染和/或细菌感染。本发明提供的中药精油不仅包含中药提取物,例如通过超临界CO2提取法或水蒸气蒸馏法提取的中药提取物,而且还包含通常用于精油制备的基油,这样制备出的中药精油不仅气味芳香,而且还具有抗菌和抗病毒的功效。
本发明还将中药精油应用到诸如口罩、消毒液、香薰、喷雾、洗手液或护肤品等日用品中,不仅可以起到抗菌和抗病毒的功效,而且味道芳香,可以使人们心情愉悦,在帮助民众预防病毒入侵、增强上呼吸道防御能力的同时,还可以使民众保持身心健康。
本发明将中药精油以药线的形式应用于口罩,通过将具有吸附作用的材料浸泡在中药精油中来制备药线,再将药线置于外层防水层和中层过滤层之间,优选地,在金属条之下的位置来制备口罩,这样一方面能避开中药精油直接接触防水层和过滤层,不会影响口罩阻隔细菌病毒的功效,另一方面,将含有中药精油的药线置于在口罩内部而不是口罩表面,也可以避免药线因掉落而失去功效。本发明所提供的口罩在不破坏口罩的防水层结构的前提下,通过在口罩的不同层次加入含有上述中药精油的药线,不仅为口罩添上各种芳香清新的气味,而且还可以起提神开窍,抗菌、抗病毒等功能。本发明提供的口罩,制作简单,成本低廉,使用方便,易于推广,并且口罩所加的药线也适用于全自动口罩生产线。
下面结合附图和实施例对本发明进行更为具体和详细的描述,实施例仅是本发明的优选实施方式,并不用于限制本发明。若无特殊说明,本发明的所有原料和试剂均为常规市场的原料、试剂。
实施例1:中药精油的配制方法
一、中药提取物的制备
1.超临界CO2提取法
将中药粉碎后加入萃取器中,向萃取器中加入少量极性溶剂(携带剂)后实现室温低压(20-30℃,100-200bar)条件,使CO2超临界流体达到亚临界流体状态,流体从下至上注入萃取器进入萃取阶段,萃取完全后,萃取液减压后先后进入第一分离器和第二分离器,在第二分离器底部收集中药提取物。
2.水蒸气蒸馏法
将粉碎后的中药放入蒸馏器内,上方接上冷却器,下方通上蒸气,使蒸气压力保持0.12Mpa-0.13Mpa。蒸气透过药粉,因蒸气的高温作用使药粉中挥发性成分气化,随水蒸气从蒸馏管进入冷却器,蒸气和气化的挥发性成分在冷却器中冷却成油水混合物,用油水分离器在冷却器出口处收集油水混合物,静置后,油水自动分离,上层为中药提取物,下层为水。使用分离器放去下层的水,即得所需的中药提取物。
二、中药精油的制备
在以下实施例中将通过超临界CO2提取法制备的中药提取物与基油以所需比例混合,以配制中药精油。
实施例2:抗新冠病毒(SARS-CoV-2)作用的研究(一)实验原理:
通过检测中药提取物样品对存在于新冠病毒(SARS-CoV-2)外壳的刺突蛋白(Spike protein)的抑制作用来表示中药提取物的抗病毒功效。当刺突蛋白被中药提取物抑制时,其与人类受体——血管紧张素转化酶2(ACE2)的结合就会降低。刺突蛋白与ACE2的结合越少,则中药提取物抑制刺突蛋白的功效越强。该方法是测试药物抗新冠病毒(SARS-CoV-2)功效的一种有效的体外检测手段。
(二)实验材料:
所用中药精油:丁香、佩兰、檀香、广藿香、莪术、金银花、艾叶、肉桂、连翘、甘草、蒲公英、紫苏叶、月桂叶、苍术、柴胡、肉豆蔻、辛夷、香茅、鱼腥草、蛇床子等;SARS-CoV-2Spike:ACE2 Inhibitor Screening Assay Kit(购自BPS Bioscience公司)进行抗新冠病毒(SARS-CoV-2)测试。
(三)实验步骤:
将浓度为1μg/mL的刺突蛋白溶液加入特制的96孔板中,每孔加50μL,4℃过夜孵育。孵育完成后,倒去上清液,用100μL封闭液A清洗3次。拍干液体,每孔加入100μL封闭液B,室温振荡1小时。拍干液体后,每孔加入20μL封闭液A,阳性对照孔和阴性对照孔中分别加入10μL 5%的DMSO水溶液,样品孔加入10μL样品溶液(含有5%DMSO),室温振荡1小时。其后,阳性对照孔加入20μL封闭液A,阳性对照以加入不含ACE2-His的封闭液A作为模拟实验最高抑制率的情况,阴性对照孔和样品孔中分别加入20μL浓度为2.5ng/μL的ACE2-His溶液,室温振荡反应1小时。反应完成后拍干液体,用100μL封闭液A清洗3次。拍干液体,每孔加入100μL封闭液B,室温培养10分钟。培养结束后拍干液体,每孔加入10μL Anti-His-HRP溶液,室温振摇培养1小时。先用100μL封闭液A清洗3次,紧接着每孔加入100μL封闭液B,室温培养10分钟。最后,拍干液体,每孔加入100μL ELISA ECL substrate A和B(1:1)的混合液,测定化学荧光强度。数据用SPSS 22进行统计分析,显著性用*表示p<0.05,用**表示p<0.01。
(四)实验结果:
如图1和图2所示,低浓度中药精油(0.1%,以体积百分比计)和高浓度中药精油(1%,以体积百分比计)均表现出有抗新冠病毒(SARS-CoV-2)作用,并且其中,丁香、佩兰、莪术、金银花、肉桂、连翘、甘草、蒲公英、紫苏叶、柴胡、辛夷、香茅、蛇床子的抗病毒效果较为显著。具体地,低浓度的佩兰、金银花、蒲公英、鱼腥草和蛇床子的中药精油对刺突蛋白与ACE2的结合的抑制作用均在90%以上,其中佩兰、蒲公英、鱼腥草和蛇床子对刺突蛋白与ACE2的结合的抑制作用几乎可达100%(图1),高浓度的丁香、佩兰、金银花、甘草、蒲公英、紫苏叶、柴胡和蛇床子的中药精油对刺突蛋白与ACE2的结合的抑制作用几乎可达100%(图2)。在图1和图2中,以5%的DMSO水溶液及不含ACE2-His的溶液为阳性对照;以5%的DMSO水溶液及含2.5ng/μL ACE2-His的溶液为阴性对照。
在这些精油中,我们进一步选取了抗病毒活性较为显著的丁香、佩兰、金银花、肉桂的中药精油,测定了它们浓度分别为0.003%、0.01%、0.03%、0.1%,0.3%和1%(以体积百分比计)时的抗新冠病毒(SARS-CoV-2)活性,结果如图3所示。由图3可以看出,在浓度为0.003%时,丁香、佩兰、金银花、肉桂精油也显示其抗病毒的能力,而且抗病毒活性与浓度呈正比关系。
(五)初步结论:
对20种中药提取物进行了抗新冠病毒(SARS-CoV-2)筛选,结果发现,三种中药提取物的抗病毒功效不明显,另外十七种提取物表现出良好的抗病毒功效,其中,丁香、佩兰、莪术、金银花、肉桂、连翘、甘草、蒲公英、紫苏叶、柴胡、辛夷、香茅、蛇床子等中药精油均表现了更好的抗新冠病毒(SARS-CoV-2)的功效。广藿香、檀香和苍术油对S蛋白的抑制作用不明显。
实施例3:中药精油的抗菌作用(一)实验菌种:
包括5种空气中常见病原菌:金黄色葡萄球菌(Staphylococcus aureus,SA);大肠杆菌(Escherichia coli,EC);铜绿假单胞菌(Pseudomonas aeruginosa,PA);肺炎克雷伯氏菌(Klebsiella peneumoniae,KP);枯草芽孢杆菌(Bacillus subtilis,BS),以及4种常见的水产养殖常见病原菌:嗜水气单胞菌(Aeromonas hydrophila,Ah);迟缓爱德华氏菌(Edwardsiella tarda,Et);解藻弧菌(Vibrio alginolyticus,Va);哈维氏弧菌(Vibrioharveyi,Vh)。所有细菌均采购自广东省微生物保藏中心。
(二)培养基:
5种气生病原菌(SA、EC、PA、KP和BS)、Ah和Et使用LB培养基,37℃培养;Va和Vh采用2216E培养基,30℃培养。
(三)实验方法:
采用滤纸片法测定提取物样品的抗菌活性,测试样品对细菌的抑菌圈大小。
(四)实验步骤:
SA、EC、PA、KP、BS、Ah和Et取100μL制备的1×105CFU/mL悬液分别涂布在LB琼脂培养基上;Va和Vh取100μL制备的1×105CFU/mL悬液分别涂布在2216E琼脂培养基上。分别在培养基表面放置浸泡过20种中药精油的滤纸片(直径6mm)并使其紧贴培养基表面,静置30分钟后,放入培养箱中,在合适的条件下培养24小时后,测量透明抑菌圈的直径。由于中药精油会在培养基中呈球形扩散,其浓度也会由内向外递减,所以形成的透明圈的直径大小与其抑菌活性强弱呈正相关关系。
(五)实验结果:
20种中药精油对九种细菌表现出不同程度的抑制生长作用,其中,肉桂提取物的抑菌活性最为显著,强于阳性对照卡那霉素(5mg/mL)。具体抗菌活性见表1。
表1.二十种中药精油的抗菌活性结果
注:SA:金黄色葡萄球菌;EC:大肠杆菌;KP:肺炎克雷伯氏菌;PA:铜绿假单胞菌;BS:枯草芽孢杆菌;Ah:嗜水气单胞菌;Et:迟缓爱德华氏菌;Va:解藻弧菌;Vh:哈维氏弧菌
(六)初步结论:
由表1的抗菌实验结果表明,肉桂、丁香、月桂叶提取物对9种细菌表现出较好的抑制作用;香茅提取物对8种细菌表现出较好的抑制活性;莪术提取物也表现对其中的5种细菌显示比较好的抑菌功效,其中肉桂提取物活性最为显著,对七种细菌的抑制活性均强于阳性对照卡那霉素(5mg/mL)。
肉桂、丁香、莪术、月桂叶和香茅对各种菌的抑制功效如图4所示。
实施例4:中药精油对皮肤刺激性和敏感性的测定
皮肤敏感测试:12个自愿受试者(5男7女,22-45岁),将中药精油(以葡萄籽油为基油)稀释成5%(体积比),涂在受试者左手手臂内侧指定位置,1小时后,记录会否有红肿、痕痒等敏感反应。观察结果显示:均未出现红肿、痕痒、脱皮、湿疹等皮肤敏感现象。
实施例5:抗病毒精油口罩的制造
根据实施例4的皮肤测试未发现过敏的结果,我们将中药精油以葡萄籽油稀释至5%(体积比),由此制备即用中药精油。随后在普通口罩的基础上进一步制造本发明的抗病毒精油口罩。
方式一:将10μL即用中药精油加至贴有双面胶的无纺棉中,至完全吸附之后,贴在一次性口罩背面最底部,由此制得本发明的一种抗病毒精油口罩。
方式二:先用本发明的中药精油浸渍具有吸附作用的棉线、棉条或无纺布条,由此获得药线2,然后将该药线固定在一次性口罩的外层3(即防水层)和中层4(即过滤层)之间靠上的位置处,例如在夹住鼻梁的金属线1下面大约1厘米处,以利于鼻粘膜吸收(图5)。通过上述方式获得了本发明的另一种抗病毒精油口罩。
需要注意,不宜将精油直接加在口罩的防水层上,因为精油分子会破坏水层和静电过滤层,使口罩失去功效。另外,上文所述的结构配置,可以避免直接接触防水层和过滤层,不影响口罩阻隔病毒和细菌的功效;另外,将药线放入口罩内部而不是置于表面,可以避免药线掉落而失去功效。
实施例6:抗病毒精油口罩的应用
派发给14-20名自愿受试者,用来预防新冠病毒的吸入。每天派发有不同中药精油的口罩和问卷调查。统计结果如下表2所示,表3显示问卷调查所包括的内容:性别、年龄、佩戴时间、能否闻到气味、味道持续时间、满意度、对人体眼、鼻和皮肤的不适感等等。
表2.佩戴具有中药精油的一次性口罩后的问卷调查统计结果
表3.八种中药精油的问卷调查具体内容
结论:由表2和表3的统计结果看出,最佳满意度的中药精油为佩兰。此外,肉桂油和柴胡油以1:1组合;以及丁香油和甘草油以及佩兰油和柴胡油以1:1组合,在问卷调查都得到比较好的满意度。
以上仅为本发明的较佳实施方案,并不用以限制本发明,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (18)
1.一种中药精油,其中,所述中药精油包含以下中药的提取物中的一种或多种:丁香、肉桂、莪术、紫苏叶、辛夷、香茅、蛇床子、佩兰、甘草、金银花、连翘、蒲公英、柴胡。
2.根据权利要求1所述的中药精油,其中所述中药的提取物通过超临界CO2提取法或水蒸气蒸馏法提取获得。
3.根据权利要求1或2所述的中药精油,其中,所述中药精油包含以下中药提取物的组合:莪术提取物+肉桂提取物、柴胡提取物+肉桂提取物、甘草提取物+丁香提取物、或佩兰提取物+柴胡提取物。
4.根据权利要求1-3中任一项所述的中药精油,其中,所述中药精油还包含作为基油的甜杏仁油、玫瑰籽油或葡萄籽油中的一种或多种。
5.根据权利要求1-4中任一项所述的中药精油,其中,以体积百分比计,所述中药精油中的每种所述提取物的浓度为0.003%~10%。
6.根据权利要求5所述的中药精油,其中,以体积百分比计,所述中药精油中的每种所述提取物的浓度为0.1%~10%。
7.一种抑制冠状病毒和/或细菌的方法,所述方法包括将权利要求1-6任一项所述的中药精油与冠状病毒和/或细菌相接触。
8.根据权利要求7所述的方法,其中,所述冠状病毒为严重急性呼吸综合征冠状病毒2号(SARS-CoV-2)、严重急性呼吸综合征冠状病毒(SARS-CoV)、中东呼吸综合征冠状病毒(MERS-CoV)或蝙蝠SARS样冠状病毒(bat-SL-CoVZC45)。
9.根据权利要求7所述的方法,其中,所述细菌为金黄色葡萄球菌(Staphylococcusaureus)、大肠杆菌(Escherichia coli)、铜绿假单胞菌(Pseudomonas aeruginosa)、肺炎克雷伯氏菌(Klebsiella peneumoniae)、枯草芽孢杆菌(Bacillus subtilis,BS)、嗜水气单胞菌(Aeromonas hydrophila)、迟缓爱德华氏菌(Edwardsiella tarda)、解藻弧菌(Vibrio alginolyticus)、哈维氏弧菌(Vibrio harveyi)中的一种或者多种。
10.根据权利要求7-9任一项所述的方法,其中,所述中药精油通过减少冠状病毒外壳的刺突蛋白来抑制冠状病毒。
11.权利要求1-6中任一项所述的中药精油在制备用于预防冠状病毒感染和/或细菌感染的制剂中的用途。
12.根据权利要求11所述的用途,其中,所述冠状病毒为严重急性呼吸综合征冠状病毒2号(SARS-CoV-2)、严重急性呼吸综合征冠状病毒(SARS-CoV)、中东呼吸综合征冠状病毒(MERS-CoV)或蝙蝠SARS样冠状病毒(bat-SL-CoVZC45)。
13.根据权利要求11所述的用途,其中,所述细菌为金黄色葡萄球菌、大肠杆菌、铜绿假单胞菌、肺炎克雷伯氏菌、枯草芽孢杆菌、嗜水气单胞菌、迟缓爱德华氏菌、解藻弧菌、哈维氏弧菌中的一种或者多种。
14.一种日用品,包含权利要求1-6中任一项所述的中药精油。
15.根据权利要求14所述的日用品,其中,所述日用品为口罩、消毒液、香薰、喷雾、洗手液或护肤品。
16.根据权利要求15所述的日用品,其中,所述日用品为口罩,并且所述中药精油以药线的形式存在于所述口罩中。
17.根据权利要求16所述的日用品,其中,所述中药精油中每种所述提取物的浓度为5%-10%,例如5%、6%、7%、8%、9%或10%。
18.根据权利要求16或17所述的日用品,其中,所述口罩为一次性口罩,包括左带、作为防水层的外层、作为过滤层的中层、作为吸水层的内层、用于夹住鼻梁的金属条和右带,并且所述药线位于所述外层和所述中层之间,例如位于所述金属条下方,例如下方0.5-2厘米。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011002501.5A CN114246925A (zh) | 2020-09-22 | 2020-09-22 | 一种中药精油及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011002501.5A CN114246925A (zh) | 2020-09-22 | 2020-09-22 | 一种中药精油及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114246925A true CN114246925A (zh) | 2022-03-29 |
Family
ID=80789578
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011002501.5A Pending CN114246925A (zh) | 2020-09-22 | 2020-09-22 | 一种中药精油及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114246925A (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115449422A (zh) * | 2022-09-14 | 2022-12-09 | 杭州香芝生物科技有限公司 | 一种萃取辛夷花油的方法 |
CN115708794A (zh) * | 2023-01-09 | 2023-02-24 | 同芙集团(中国)股份有限公司 | 一种抑菌精华油 |
CN116058388A (zh) * | 2023-02-01 | 2023-05-05 | 徐宝华 | 一种可杀菌和抑制病毒的组合物及应用 |
CN116211962A (zh) * | 2023-02-07 | 2023-06-06 | 广州美思生物技术有限公司 | 一种除螨抑菌消痘改善脂溢性皮炎的天然植物皮肤抑菌液 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108853277A (zh) * | 2017-05-12 | 2018-11-23 | 王月梅 | 一种用于针灸的中药消毒液 |
CN111280526A (zh) * | 2020-03-26 | 2020-06-16 | 贾斌 | 用于预防流感病毒和/或新型冠状病毒引起的肺炎的口罩及其制备方法 |
CN111297949A (zh) * | 2020-03-19 | 2020-06-19 | 王鹏 | 一种精油口罩及其制备方法 |
-
2020
- 2020-09-22 CN CN202011002501.5A patent/CN114246925A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108853277A (zh) * | 2017-05-12 | 2018-11-23 | 王月梅 | 一种用于针灸的中药消毒液 |
CN111297949A (zh) * | 2020-03-19 | 2020-06-19 | 王鹏 | 一种精油口罩及其制备方法 |
CN111280526A (zh) * | 2020-03-26 | 2020-06-16 | 贾斌 | 用于预防流感病毒和/或新型冠状病毒引起的肺炎的口罩及其制备方法 |
Non-Patent Citations (10)
Title |
---|
MUHAMMAD ASIF等: "COVID‑19 and therapy with essential oils having antiviral,anti‑inflammatory, and immunomodulatory properties", 《INFLAMMOPHARMACOLOGY》 * |
周峰等: "十二种中药挥发油及其滤液体外抗菌活性研究", 《食品科学》 * |
姜程曦等: "莪术油注射液协同治疗新型冠状病毒肺炎(COVID-19)可行性浅析", 《中草药》 * |
张婷婷等: "辛夷挥发油GC-MS分析及其抗氧化、抗菌活性", 《食品科学》 * |
张金宝等: "蛇床子挥发油的提取方法及其化学成分的气相色谱分析", 《理化检验-化学分册》 * |
徐小娜等: "基于 GC-MS 结合 HELP 法的药对金银花—连翘及其单味药挥发性化学成分分析", 《南昌工程学院学报》 * |
杨超等: "蒲公英挥发油成分分析及其抗炎抗肿瘤活性研究", 《中华中医药杂志》 * |
詹益兴等: "《绿色精细化工——天然产品制造法(第2集)》", 31 July 2006, 科学技术文献出版社 * |
豆康宁等: "响应面优化超声波辅助提取甘草精油工艺研究", 《中国调味品》 * |
银艳桃等: "中药挥发油预防新型冠状病毒肺炎刍议", 《医学争鸣》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115449422A (zh) * | 2022-09-14 | 2022-12-09 | 杭州香芝生物科技有限公司 | 一种萃取辛夷花油的方法 |
CN115708794A (zh) * | 2023-01-09 | 2023-02-24 | 同芙集团(中国)股份有限公司 | 一种抑菌精华油 |
CN116058388A (zh) * | 2023-02-01 | 2023-05-05 | 徐宝华 | 一种可杀菌和抑制病毒的组合物及应用 |
CN116211962A (zh) * | 2023-02-07 | 2023-06-06 | 广州美思生物技术有限公司 | 一种除螨抑菌消痘改善脂溢性皮炎的天然植物皮肤抑菌液 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Van Wyk et al. | Medicinal plants of the world | |
CN106538638B (zh) | 一种中药消毒剂及其制备方法 | |
Jaiarj et al. | Anticough and antimicrobial activities of Psidium guajava Linn. leaf extract | |
Sultana et al. | Cough suppressant herbal drugs: A review | |
Batiha et al. | A review of the bioactive components and pharmacological properties of Lavandula species | |
CN114246925A (zh) | 一种中药精油及其应用 | |
Manganelli et al. | Ethnopharmacobotanical studies of the Tuscan Archipelago | |
US8496978B2 (en) | Anti-fever botanical composition and uses thereof | |
WO2011026267A1 (zh) | 用于消炎消肿止痛的中草药组合物、制备方法及其应用 | |
CN102940719A (zh) | 治疗奶牛***炎的中草药饲料添加剂 | |
Natarajan et al. | An ethnopharmacological study from Thane district, Maharashtra, India: Traditional knowledge compared with modern biological science | |
CN112841233A (zh) | 一种中药农药杀虫剂 | |
Kaushik et al. | Chemical constituents, pharmacological activities, and uses of common ayurvedic medicinal plants: a future source of new drugs | |
Hurinanthan | Anti-HIV activity of selected South African medicinal plants | |
CN104491121A (zh) | 一种用于治疗呼吸道疾病的抗菌精华液及其制备方法 | |
CN108553572A (zh) | 一种功能性熏香及其制备方法 | |
Raghunathan | An ethnomedicinal survey of medicinal plants utilized by folk people of the Thrissur forest circle, Kerala | |
Usman | Poisonous Herbal Plants: NA | |
Mounika et al. | Invitro evaluation of antimicrobial activity of Clove buds (Euginea aromatica) | |
ERUÇAR et al. | Ethnobotanical records of medicinal plants of Turkey effective on stress management Complied with the literature survey in their chemical content and activities | |
Otimanam et al. | Cutaneous wound healing activity of herbal ointment containing Tetrapleura tetraptera fruit extract | |
CN104814047A (zh) | 一种b超室消毒用中药组合物消毒液 | |
Singh et al. | Antiviral effects of medicinal plants and their active phytochemical constituents against respiratory diseases and associated biological functions | |
Lawal et al. | A Study of the Phytochemical Properties and Synergistic Antibacterial Activity of Annona comosus (LINN) Merr. Peel and Citrus senensis Peel Extracts on Aeromonas hydrophila and Salmonella species. | |
Dhar et al. | Medicinal Plants of India |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220329 |